<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/05F17A40-A0E2-4FF2-BC89-81C0CCE9A7D7"><gtr:id>05F17A40-A0E2-4FF2-BC89-81C0CCE9A7D7</gtr:id><gtr:name>Washington University at St Louis</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Unknown</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/05F17A40-A0E2-4FF2-BC89-81C0CCE9A7D7"><gtr:id>05F17A40-A0E2-4FF2-BC89-81C0CCE9A7D7</gtr:id><gtr:name>Washington University at St Louis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6433BAE5-5750-4CAF-B009-AD2597263DB8"><gtr:id>6433BAE5-5750-4CAF-B009-AD2597263DB8</gtr:id><gtr:firstName>Rajesh</gtr:firstName><gtr:surname>Thakker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1000467"><gtr:id>148D2DBA-D88D-4CBB-AD5C-09E3ACD4391C</gtr:id><gtr:title>Molecular Mechanisms and Therapies for Parathyroid and Neuroendocrine Disorders</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000467</gtr:grantReference><gtr:abstractText>Abnormal hormone secretion from endocrine glands can disrupt the regulation of many body processes, thereby causing diseases in different organs. This is well illustrated by disorders of parathyroid hormone (PTH) which regulates body calcium, by controlling the balance between the amounts that are absorbed from the gut, deposited into bone and into cells, and excreted from the kidney. Over-secretion of PTH due to parathyroid tumours, which affect 3:1,000 of the adult population and 1% of postmenopausal women, is the major cause of a rise in plasma calcium and may be associated with kidney stones, renal failure, osteoporosis and ulcers. Moreover, parathyroid tumours can occur in association with other endocrine tumours that involve neuroendocrine cells of the pancreas and pituitary. These neuroendocrine tumours may also occur as isolated endocrinopathies that affect 5.5:1,000 adults. The pancreatic neuroendocrine tumours may be associated with ulcers, diarrhoea, and seizures due to a low plasma glucose; and the pituitary neuroendocrine tumours may be associated with infertility, impotence, high blood pressure and diabetes. Current treatments for these endocrine tumours are not always effective, and a better understanding of their causes, which are likely to have a genetic basis, will facilitate improvements in diagnosis and treatments. We have therefore been pursuing studies to identify these genes with the aims of elucidating the underlying mechanisms in these disorders of parathyroid and neuroendocrine tumours. In the course of these studies we have characterised the genetic abnormalities and mechanisms for 14 disorders of calcium homeostasis and bone metabolism, kidney stones and endocrine tumours. We have also translated these advances to: improve diagnosis and management; formulate guidelines; establish proof of principle for gene replacement therapy for endocrine tumours in a mouse model; and identify abnormalities in cellular signalling pathways. We now propose, in a continuation of this programme, to elucidate further the functions of the genes that we have recently identified, and to develop new avenues for drug design and gene therapy. This is likely to have further clinical impacts in the management of patients with parathyroid and neuroendocrine tumours, kidney stones, renal failure and osteoporosis. The results are published in high quality journals, presented at national and international conferences, and form the basis of contributions to book chapters and review articles. The applicant has also provided expert information to the media (e.g. New York Times), patient supports groups (AMEND), and he will continue to undertake this.</gtr:abstractText><gtr:technicalSummary>Our research is focussed on investigating the molecular mechanisms underlying parathyroid and neuroendocrine disorders, with the aim of translating these advances into clinical practice by facilitating improvements in diagnosis and management, and of establishing in vitro and in vivo models for exploring new pharmacological and gene replacement therapies. Parathyroid tumours are common and major causes of abnormal calcium and bone metabolism, and may occur as an isolated endocrinopathy or in association with neuroendocrine tumours (NETs) of the pancreas and pituitary, as in multiple endocrine neoplasia type 1 (MEN1). During 2004-2009, we showed that: mutational analysis can solve diagnostic errors due to MEN1 phenocopies which occur in 5% of families; asymptomatic children with MEN1 mutations harbour non-functioning pancreatic NETs, thereby indicating a revision of the current international guidelines for screening; patients with germline MEN1 mutations may develop only parathyroid tumours and not NETs, implicating a role for genetic modifiers; pituitary NETs with loss of the MEN1 gene have abnormalities of proliferative (Wnt/beta-catenin) and apoptotic (Bcl2) pathways, down-regulation of tumour suppressor microRNAs (miR-15a-miR16-1) and upregulation of oncogenic microRNAs (miR130b); Men1 gene replacement therapy can decrease the proliferation rate of pituitary NETs in Men1+/- mice; inactivating mutations of the calcium-sensing receptor (CaSR), a G-protein coupled receptor (GPCR), which cause familial benign hypocalciuric hypercalcaemia type 1 (FBHH1) can be associated with parathyroid tumours in adults; an allosteric modulator of the CaSR can correct hypocalcaemia in a mouse model with an activating CaSR mutation that represents a model for autosomal dominant hypocalcaemic hypercalciuria type 1 (ADHH1); mutations in the G-protein, Galpha11, are associated with FBHH2 and ADHH2; and patients with FBHH3 have involvement of an as yet unidentified gene on chromosome 19q13. We now propose in a continuation of this programme to elucidate: 1) the genetic mechanisms and pathways underlying parathyroid and neuroendocrine tumourigenesis, by investigating the roles of the Galpha11, FBHH3, and MEN1 genes, and microRNAs; and 2) undertake pre-clinical studies using in vitro and in vivo models that would facilitate the implementation of new treatments e.g. targeted-peptides, gene therapy and microRNA therapy, for NETs and disorders of calcium homeostasis. Knowledge gained from these studies, will contribute to improved diagnostic and therapeutic strategies in these endocrine disorders. My group has made internationally leading contributions to this field which is ideally placed at the basic science and clinical interface, and fits with the MRC strategic priorities of: genetics and disease; and translation of research.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1899982</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Mary Lyon Centre</gtr:department><gtr:description>Cox, R</gtr:description><gtr:id>A90A5758-2519-4DA4-B721-25DACBCE6B72</gtr:id><gtr:impact>Several papers, full details under publications.</gtr:impact><gtr:partnerContribution>Brought together different expertise and resources to answer a biological question.</gtr:partnerContribution><gtr:piContribution>Undertaken molecular genetic studies and mouse phenotyping analysis together with details for publication.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Washington University at St Louis</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Dr M P Whyte, USA</gtr:description><gtr:id>D1A20435-CCF5-4EAD-9C8A-70F79E83B71F</gtr:id><gtr:impact>19809483 16167084</gtr:impact><gtr:piContribution>Undertook molecular analysis and detailed scientific studies for the XLHPT project published in JCI 2005.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Mammalian Genetics Unit</gtr:department><gtr:description>Brown, S</gtr:description><gtr:id>E1AFCF00-EF04-4140-9DF9-3C8D9121FEA0</gtr:id><gtr:impact>20457824</gtr:impact><gtr:partnerContribution>Brought together different expertise and resources to answer a biological question.</gtr:partnerContribution><gtr:piContribution>Undertaken molecular genetic studies and mouse phenotyping analysis together with details for publication.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>AMEND Patient Support Group</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>728F1FB0-1C05-48E1-B2BC-91320385EE47</gtr:id><gtr:impact>Approximately 200 patients and their relatives attended the talk which raised important and interesting questions with discussions thereafter. The venue was at a hotel in Rugby (UK) over a weekend.

Raised interest amongst patients for the need for medical research.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Association of Multiple Endocrine Neoplasia Disorders (AMEND) patient support group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DC126A57-4E21-4913-88CB-96A3FC921A58</gtr:id><gtr:impact>Helping to produce newsletters, and a video / DVD for patients. Also helping to establish similar patient groups in Europe (meeting held in Italy 2010).

AMEND support group have reported a high level of interest in the video and are making copies to be distributed internationally.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Placement for 6th form school pupil</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6AB903BA-0E3C-4B11-AC1F-55A5CBD3E372</gtr:id><gtr:impact>Encouraging school pupils to take up careers in medicine and science.

Student is plannign to apply to medical school.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work placement for undergraduate.</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>85B854FE-A00B-4A39-9B00-27FC696BE5E9</gtr:id><gtr:impact>One student worked in the lab for one month.

One abstract and one peer reviewed publication achieved.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Placement for undergraduate student</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C273666E-AB7A-47B6-9D10-BD55CFE63E36</gtr:id><gtr:impact>Undergraduate student undertook a research project for one month and continued for the next year on a part time basis to complete this for final honors degree.

Degree obtained. Presentation of abstract at national British Endocrine Societies meeting.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collabortive Grant</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>3A411082-66BD-4B7A-B867-4F81AD0EE8A6</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Clinical Training Fellowship - A Rogers</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>C9FEF1CF-8A14-442A-8310-0A00279F620C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collaborative Grant</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>E23B259A-B0EA-44DE-A62A-A8FFF2196E5C</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>315000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>Rare Diseases Translational Research Collaboration</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>5233B137-AED0-43E2-91CB-F16D4669D1CA</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship - K Gaynor</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>EEB39803-C064-44DE-858D-571ACACEC0B6</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Treat-OA</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>422A9F37-03CD-4DAB-B999-BBD7718EC259</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Clinical Training Fellowship - S Howles</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>10A83585-9023-42A4-880B-74FA0D4FF168</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Clinical Training Fellowship - M Javid</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>DD6FDED4-259B-4347-A43A-C673458441DF</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship - C Gorvin</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C37B7F8C-6277-4930-ABDB-A5C6E8C71393</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EU Marie Curie Initial Training Network - V Babinsky</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Community Research and Development Information Service (CORDIS)</gtr:fundingOrg><gtr:id>D7420699-D30D-4B47-82C8-04521FA03A90</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Clinical guidelines on multiple endocrine neoplasia type 1</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>ABBA167C-F0F1-4C8C-8EF9-9FA8DBDAF49E</gtr:id><gtr:impact>These guideliines will have impact on improvements in clinical service. Published: Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Tonelli F, Brandi ML (2012). Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). Journal of Clinical Endocrinology &amp;amp; Metabolism, 97: 2990-3011.</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Clinical guidelines for neuroendocrine tumours</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DF94074C-0E4A-422D-BFDA-6EB71470A34B</gtr:id><gtr:impact>These guidelines will improve survival, quality of life and clinical practice. Published: Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB (2012). Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut, 61: 6-32.</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/692C12D6-7456-4B1F-8292-82019BF85EB6"><gtr:id>692C12D6-7456-4B1F-8292-82019BF85EB6</gtr:id><gtr:title>Molecular genetic advances in pituitary tumor development</gtr:title><gtr:parentPublicationTitle>Expert Review of Endocrinology &amp; Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2c8e1b1c59ffd63fbc68f136cf62c76b"><gtr:id>2c8e1b1c59ffd63fbc68f136cf62c76b</gtr:id><gtr:otherNames>Yates C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/28A1FB2B-433D-406E-9509-7E2D6ABB7CF7"><gtr:id>28A1FB2B-433D-406E-9509-7E2D6ABB7CF7</gtr:id><gtr:title>Mutational analysis of the adaptor protein 2 sigma subunit (AP2S1) gene: search for autosomal dominant hypocalcemia type 3 (ADH3).</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b64fe6ed8f54145940378d4d138c74f5"><gtr:id>b64fe6ed8f54145940378d4d138c74f5</gtr:id><gtr:otherNames>Rogers A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B1E21BD5-783A-4C23-8104-62BC72C6D36E"><gtr:id>B1E21BD5-783A-4C23-8104-62BC72C6D36E</gtr:id><gtr:title>HDR syndrome: a follow-up genotype-phenotype analysis of a de novo missense Thr272Ile mutation in exon 4 of GATA3.</gtr:title><gtr:parentPublicationTitle>Klinische Padiatrie</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f4a712c1ab30617423392b7414b5356f"><gtr:id>f4a712c1ab30617423392b7414b5356f</gtr:id><gtr:otherNames>Gomes TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-8630</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B695BA81-424C-4C41-A093-6DE6135E0E54"><gtr:id>B695BA81-424C-4C41-A093-6DE6135E0E54</gtr:id><gtr:title>Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4afd07a38cd306c5f99be9de1030ef21"><gtr:id>4afd07a38cd306c5f99be9de1030ef21</gtr:id><gtr:otherNames>Loh NY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF84D00D-B00F-48A6-8C81-E79BCD92C87B"><gtr:id>BF84D00D-B00F-48A6-8C81-E79BCD92C87B</gtr:id><gtr:title>Association between genotype and phenotype in uromodulin-associated kidney disease.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0a449d323ce37bc7850b73c7739b6a3e"><gtr:id>0a449d323ce37bc7850b73c7739b6a3e</gtr:id><gtr:otherNames>Moskowitz JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2215F80F-DC3E-48AC-85D8-EFE845A067AF"><gtr:id>2215F80F-DC3E-48AC-85D8-EFE845A067AF</gtr:id><gtr:title>Management of Hypoparathyroidism: Summary Statement and Guidelines.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e2b0fa06b52531fc2a2902415a7dab53"><gtr:id>e2b0fa06b52531fc2a2902415a7dab53</gtr:id><gtr:otherNames>Brandi ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8E78F180-2B98-405C-AADC-4317837AB58C"><gtr:id>8E78F180-2B98-405C-AADC-4317837AB58C</gtr:id><gtr:title>miR-135b- and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef533ce3bffd02e386eb5151244f39d8"><gtr:id>ef533ce3bffd02e386eb5151244f39d8</gtr:id><gtr:otherNames>Fetahu IS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/24422130-97BD-4D19-A0E4-87E3CD4A7DE2"><gtr:id>24422130-97BD-4D19-A0E4-87E3CD4A7DE2</gtr:id><gtr:title>Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice.</gtr:title><gtr:parentPublicationTitle>Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4012bab03e044a389467d6bd29325d39"><gtr:id>4012bab03e044a389467d6bd29325d39</gtr:id><gtr:otherNames>Newey PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1530-891X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D8047980-C07A-443A-9291-C5E3E1D9417D"><gtr:id>D8047980-C07A-443A-9291-C5E3E1D9417D</gtr:id><gtr:title>Significant deterioration in nanomechanical quality occurs through incomplete extrafibrillar mineralization in rachitic bone: evidence from in-situ synchrotron X-ray scattering and backscattered electron imaging.</gtr:title><gtr:parentPublicationTitle>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/485fae73aaa56c4f03380b50f6866902"><gtr:id>485fae73aaa56c4f03380b50f6866902</gtr:id><gtr:otherNames>Karunaratne A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0884-0431</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B16022B9-1C93-4D5D-95B4-FD4F890D8C61"><gtr:id>B16022B9-1C93-4D5D-95B4-FD4F890D8C61</gtr:id><gtr:title>Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/08a67913704857049cd961e429f8dd62"><gtr:id>08a67913704857049cd961e429f8dd62</gtr:id><gtr:otherNames>Walls GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A7717EC9-BD39-42FC-88A2-9DCA25740480"><gtr:id>A7717EC9-BD39-42FC-88A2-9DCA25740480</gtr:id><gtr:title>The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1).</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2fb3e361f4680064c89a62f1e0816aa4"><gtr:id>2fb3e361f4680064c89a62f1e0816aa4</gtr:id><gtr:otherNames>Hannan FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2A7063C9-A652-4268-9212-7F6DBD0D0ED5"><gtr:id>2A7063C9-A652-4268-9212-7F6DBD0D0ED5</gtr:id><gtr:title>A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0fe10ebdb8ef07071e879e1ba8081ed4"><gtr:id>0fe10ebdb8ef07071e879e1ba8081ed4</gtr:id><gtr:otherNames>Esapa CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1443D255-DCF6-44EE-8504-7BE8F5D3B16F"><gtr:id>1443D255-DCF6-44EE-8504-7BE8F5D3B16F</gtr:id><gtr:title>Epidemiology and Diagnosis of Hypoparathyroidism.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a006a4434b33b20be6a66ceb6cf50094"><gtr:id>a006a4434b33b20be6a66ceb6cf50094</gtr:id><gtr:otherNames>Clarke BL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F401F6D0-4A31-432A-BA90-066B96C2AE48"><gtr:id>F401F6D0-4A31-432A-BA90-066B96C2AE48</gtr:id><gtr:title>Calcium-sensing receptor (CaSR) mutations and disorders of calcium, electrolyte and water metabolism.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical endocrinology &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2fb3e361f4680064c89a62f1e0816aa4"><gtr:id>2fb3e361f4680064c89a62f1e0816aa4</gtr:id><gtr:otherNames>Hannan FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1521-690X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/435311C2-71C6-49ED-904B-526C81D566B6"><gtr:id>435311C2-71C6-49ED-904B-526C81D566B6</gtr:id><gtr:title>Guidelines for the management of thyroid cancer.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cb44723b4b9da181ab2eeaaf7e483c77"><gtr:id>cb44723b4b9da181ab2eeaaf7e483c77</gtr:id><gtr:otherNames>Perros P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E7FC8528-2FC6-4E82-A5A8-B62C851B0076"><gtr:id>E7FC8528-2FC6-4E82-A5A8-B62C851B0076</gtr:id><gtr:title>Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f588712875eb3f2079940bef7af8448"><gtr:id>6f588712875eb3f2079940bef7af8448</gtr:id><gtr:otherNames>Nesbit MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/44A448E4-19F5-4C0D-9606-FC140857F46E"><gtr:id>44A448E4-19F5-4C0D-9606-FC140857F46E</gtr:id><gtr:title>Animal models of pituitary neoplasia.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9f4cc013f35def12bb324155e5e926b6"><gtr:id>9f4cc013f35def12bb324155e5e926b6</gtr:id><gtr:otherNames>Lines KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DBFADC82-A6B9-41E7-8BE8-54412CF5A879"><gtr:id>DBFADC82-A6B9-41E7-8BE8-54412CF5A879</gtr:id><gtr:title>Presentation of Hypoparathyroidism: Etiologies and Clinical Features.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4b6ce20ac7a999415ccd3bdbe8f76a2f"><gtr:id>4b6ce20ac7a999415ccd3bdbe8f76a2f</gtr:id><gtr:otherNames>Shoback DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8B46A869-9F5C-466C-A6DE-CF47192D4082"><gtr:id>8B46A869-9F5C-466C-A6DE-CF47192D4082</gtr:id><gtr:title>A mouse model of early-onset renal failure due to a xanthine dehydrogenase nonsense mutation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9d1ac2130962ee63f2defcb9b59a8461"><gtr:id>9d1ac2130962ee63f2defcb9b59a8461</gtr:id><gtr:otherNames>Piret SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AE029F5A-852E-4E69-8572-A7AADAA955D9"><gtr:id>AE029F5A-852E-4E69-8572-A7AADAA955D9</gtr:id><gtr:title>N-ethyl-N-Nitrosourea (ENU) induced mutations within the klotho gene lead to ectopic calcification and reduced lifespan in mouse models.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0fe10ebdb8ef07071e879e1ba8081ed4"><gtr:id>0fe10ebdb8ef07071e879e1ba8081ed4</gtr:id><gtr:otherNames>Esapa CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6AFA3B84-3CD9-4E7F-BE35-A477DA92DF79"><gtr:id>6AFA3B84-3CD9-4E7F-BE35-A477DA92DF79</gtr:id><gtr:title>GATA3 mutations found in breast cancers may be associated with aberrant nuclear localization, reduced transactivation and cell invasiveness.</gtr:title><gtr:parentPublicationTitle>Hormones &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/93e808505e64ab355d2468c6eae119ec"><gtr:id>93e808505e64ab355d2468c6eae119ec</gtr:id><gtr:otherNames>Gaynor KU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1868-8497</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1402EE3F-992A-4A71-93F3-0624FD8EE7F4"><gtr:id>1402EE3F-992A-4A71-93F3-0624FD8EE7F4</gtr:id><gtr:title>MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/08a67913704857049cd961e429f8dd62"><gtr:id>08a67913704857049cd961e429f8dd62</gtr:id><gtr:otherNames>Walls GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/625A9042-FC02-45DF-993F-2FBEA6714837"><gtr:id>625A9042-FC02-45DF-993F-2FBEA6714837</gtr:id><gtr:title>Transcription factors in parathyroid development: lessons from hypoparathyroid disorders.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b08bc1da63361198efc47ffc07daa23c"><gtr:id>b08bc1da63361198efc47ffc07daa23c</gtr:id><gtr:otherNames>Grigorieva IV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/170A46F0-7A27-43A0-87BA-C16F0A89BD2E"><gtr:id>170A46F0-7A27-43A0-87BA-C16F0A89BD2E</gtr:id><gtr:title>Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b52b61d3e3709d22522d044d591de5c9"><gtr:id>b52b61d3e3709d22522d044d591de5c9</gtr:id><gtr:otherNames>Thakker RV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C77EC3F3-29AE-4005-A5FA-0A163B39A914"><gtr:id>C77EC3F3-29AE-4005-A5FA-0A163B39A914</gtr:id><gtr:title>Epidemiology of uromodulin-associated kidney disease - results from a nation-wide survey.</gtr:title><gtr:parentPublicationTitle>Nephron extra</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fdbff21a38db85d0b1f71ddff60c3dc1"><gtr:id>fdbff21a38db85d0b1f71ddff60c3dc1</gtr:id><gtr:otherNames>Lhotta K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1664-5529</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/94C6B0B8-6484-4555-B319-E395F7269E5B"><gtr:id>94C6B0B8-6484-4555-B319-E395F7269E5B</gtr:id><gtr:title>Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype-phenotype correlations, codon bias and dominant-negative effects.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2fb3e361f4680064c89a62f1e0816aa4"><gtr:id>2fb3e361f4680064c89a62f1e0816aa4</gtr:id><gtr:otherNames>Hannan FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C05AE4EF-402E-493B-BD63-F400E3EAE5A3"><gtr:id>C05AE4EF-402E-493B-BD63-F400E3EAE5A3</gtr:id><gtr:title>Cinacalcet for Symptomatic Hypercalcemia Caused by AP2S1 Mutations.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/57ed3785894d2593d33f95af70ae8b5b"><gtr:id>57ed3785894d2593d33f95af70ae8b5b</gtr:id><gtr:otherNames>Howles SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/681169ED-2F05-4976-8463-EADD3B3041A2"><gtr:id>681169ED-2F05-4976-8463-EADD3B3041A2</gtr:id><gtr:title>Hypophosphatemic rickets is associated with disruption of mineral orientation at the nanoscale in the flat scapula bones of rachitic mice with development.</gtr:title><gtr:parentPublicationTitle>Bone</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/485fae73aaa56c4f03380b50f6866902"><gtr:id>485fae73aaa56c4f03380b50f6866902</gtr:id><gtr:otherNames>Karunaratne A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1873-2763</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D64A735B-40D8-4065-95C4-D57D907B0CE0"><gtr:id>D64A735B-40D8-4065-95C4-D57D907B0CE0</gtr:id><gtr:title>Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9a0481551021c409f7506d2f06ea4564"><gtr:id>9a0481551021c409f7506d2f06ea4564</gtr:id><gtr:otherNames>Duncan EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E359A4B6-23BA-4B03-9A1E-5F8BC82AFBFE"><gtr:id>E359A4B6-23BA-4B03-9A1E-5F8BC82AFBFE</gtr:id><gtr:title>GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3718206226347df518c75fe2f24c131a"><gtr:id>3718206226347df518c75fe2f24c131a</gtr:id><gtr:otherNames>Lemos MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/37FBCF14-04BB-432A-BACC-022B529A5269"><gtr:id>37FBCF14-04BB-432A-BACC-022B529A5269</gtr:id><gtr:title>Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dee9c93c96987243379959207c4e7dca"><gtr:id>dee9c93c96987243379959207c4e7dca</gtr:id><gtr:otherNames>Eastell R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D487825-21F7-4734-875A-54340D2FE02C"><gtr:id>5D487825-21F7-4734-875A-54340D2FE02C</gtr:id><gtr:title>Mutations affecting G-protein subunit a11 in hypercalcemia and hypocalcemia.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f588712875eb3f2079940bef7af8448"><gtr:id>6f588712875eb3f2079940bef7af8448</gtr:id><gtr:otherNames>Nesbit MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C93FE254-6680-496D-9260-E06FF9706E10"><gtr:id>C93FE254-6680-496D-9260-E06FF9706E10</gtr:id><gtr:title>Identification of a G-Protein Subunit-a11 Gain-of-Function Mutation, Val340Met, in a Family With Autosomal Dominant Hypocalcemia Type 2 (ADH2).</gtr:title><gtr:parentPublicationTitle>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9d1ac2130962ee63f2defcb9b59a8461"><gtr:id>9d1ac2130962ee63f2defcb9b59a8461</gtr:id><gtr:otherNames>Piret SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0884-0431</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7C8422A8-FE28-4B0E-8C31-A65E2CE46DE9"><gtr:id>7C8422A8-FE28-4B0E-8C31-A65E2CE46DE9</gtr:id><gtr:title>Pseudohypoparathyroidism type 1a due to a novel mutation in the GNAS gene.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3718206226347df518c75fe2f24c131a"><gtr:id>3718206226347df518c75fe2f24c131a</gtr:id><gtr:otherNames>Lemos MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9E2A9844-8296-4956-AF0C-D9C6548C710F"><gtr:id>9E2A9844-8296-4956-AF0C-D9C6548C710F</gtr:id><gtr:title>Association studies of calcium-sensing receptor (CaSR) polymorphisms with serum concentrations of glucose and phosphate, and vascular calcification in renal transplant recipients.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d58083c75b1d9f7c09d81ffcaaabb06"><gtr:id>4d58083c75b1d9f7c09d81ffcaaabb06</gtr:id><gtr:otherNames>Babinsky VN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6810E190-BBD3-4660-B2C2-0190369310C8"><gtr:id>6810E190-BBD3-4660-B2C2-0190369310C8</gtr:id><gtr:title>CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8a1dae580c251b82000f5e5d0fa5eefa"><gtr:id>8a1dae580c251b82000f5e5d0fa5eefa</gtr:id><gtr:otherNames>Korpi-Hy?v?lti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A2F4311B-F94E-496E-80ED-2B49B02A9B7C"><gtr:id>A2F4311B-F94E-496E-80ED-2B49B02A9B7C</gtr:id><gtr:title>Confusing genes: a patient with MEN2A and Cushing's disease.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f20a10a80eb411f12a475181db51d12"><gtr:id>3f20a10a80eb411f12a475181db51d12</gtr:id><gtr:otherNames>Naziat A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/22F9F6EF-06B5-4D30-893F-D72579BBBBA8"><gtr:id>22F9F6EF-06B5-4D30-893F-D72579BBBBA8</gtr:id><gtr:title>Mutant prolactin receptor and familial hyperprolactinemia.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4012bab03e044a389467d6bd29325d39"><gtr:id>4012bab03e044a389467d6bd29325d39</gtr:id><gtr:otherNames>Newey PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B6133D78-72C1-4B0A-8724-6CA1B01789E6"><gtr:id>B6133D78-72C1-4B0A-8724-6CA1B01789E6</gtr:id><gtr:title>Kidney stones: a fetal origins hypothesis.</gtr:title><gtr:parentPublicationTitle>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/57ed3785894d2593d33f95af70ae8b5b"><gtr:id>57ed3785894d2593d33f95af70ae8b5b</gtr:id><gtr:otherNames>Howles SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0884-0431</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BFEBAF86-0CDC-47BE-93CA-EE17AAC53661"><gtr:id>BFEBAF86-0CDC-47BE-93CA-EE17AAC53661</gtr:id><gtr:title>Whole-exome sequencing studies of nonfunctioning pituitary adenomas.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4012bab03e044a389467d6bd29325d39"><gtr:id>4012bab03e044a389467d6bd29325d39</gtr:id><gtr:otherNames>Newey PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C0987F5E-F9F8-497A-A685-B8241B23ED94"><gtr:id>C0987F5E-F9F8-497A-A685-B8241B23ED94</gtr:id><gtr:title>Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1</gtr:title><gtr:parentPublicationTitle>The Lancet Diabetes &amp; Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2c8e1b1c59ffd63fbc68f136cf62c76b"><gtr:id>2c8e1b1c59ffd63fbc68f136cf62c76b</gtr:id><gtr:otherNames>Yates C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1EAEE9F0-59A9-4A67-9391-82C892332ABA"><gtr:id>1EAEE9F0-59A9-4A67-9391-82C892332ABA</gtr:id><gtr:title>Symmetrically reduced stiffness and increased extensibility in compression and tension at the mineralized fibrillar level in rachitic bone.</gtr:title><gtr:parentPublicationTitle>Bone</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/485fae73aaa56c4f03380b50f6866902"><gtr:id>485fae73aaa56c4f03380b50f6866902</gtr:id><gtr:otherNames>Karunaratne A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1873-2763</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ABAC0A4B-C24B-4A68-9CC5-0FBE891AF097"><gtr:id>ABAC0A4B-C24B-4A68-9CC5-0FBE891AF097</gtr:id><gtr:title>Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/57bfd23563e2f6c66080ca86a3f4b020"><gtr:id>57bfd23563e2f6c66080ca86a3f4b020</gtr:id><gtr:otherNames>D?nes J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E9B9C781-6CFA-460A-B9C8-D0B2C7B4E1DA"><gtr:id>E9B9C781-6CFA-460A-B9C8-D0B2C7B4E1DA</gtr:id><gtr:title>Receptor-mediated endocytosis and endosomal acidification is impaired in proximal tubule epithelial cells of Dent disease patients.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/be3d7fbaa94ddd1c4d54cd8939adddda"><gtr:id>be3d7fbaa94ddd1c4d54cd8939adddda</gtr:id><gtr:otherNames>Gorvin CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7464D525-333B-4825-8171-9AF0E9F9BE78"><gtr:id>7464D525-333B-4825-8171-9AF0E9F9BE78</gtr:id><gtr:title>Allosteric Modulation of the Calcium-sensing Receptor Rectifies Signaling Abnormalities Associated with G-protein a-11 Mutations Causing Hypercalcemic and Hypocalcemic Disorders.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d58083c75b1d9f7c09d81ffcaaabb06"><gtr:id>4d58083c75b1d9f7c09d81ffcaaabb06</gtr:id><gtr:otherNames>Babinsky VN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/139B5FF9-D152-41CA-9731-AA1627672591"><gtr:id>139B5FF9-D152-41CA-9731-AA1627672591</gtr:id><gtr:title>Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0595a7d8bf7c30b67c83c71fcc8d9e98"><gtr:id>0595a7d8bf7c30b67c83c71fcc8d9e98</gtr:id><gtr:otherNames>Taylor JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/04DEA56C-D7C0-4411-AC2B-A5FF4FD53E4C"><gtr:id>04DEA56C-D7C0-4411-AC2B-A5FF4FD53E4C</gtr:id><gtr:title>Clinically relevant genetic advances in endocrinology.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b64fe6ed8f54145940378d4d138c74f5"><gtr:id>b64fe6ed8f54145940378d4d138c74f5</gtr:id><gtr:otherNames>Rogers A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/27E0052B-4EDE-46A3-99AB-6C4B04B4F9CE"><gtr:id>27E0052B-4EDE-46A3-99AB-6C4B04B4F9CE</gtr:id><gtr:title>Mouse models for inherited endocrine and metabolic disorders.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9d1ac2130962ee63f2defcb9b59a8461"><gtr:id>9d1ac2130962ee63f2defcb9b59a8461</gtr:id><gtr:otherNames>Piret SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EB26FBE7-1E5C-4C27-8F1B-AD4B2454794D"><gtr:id>EB26FBE7-1E5C-4C27-8F1B-AD4B2454794D</gtr:id><gtr:title>Proliferation rates of multiple endocrine neoplasia type 1 (MEN1)-associated tumors.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/08a67913704857049cd961e429f8dd62"><gtr:id>08a67913704857049cd961e429f8dd62</gtr:id><gtr:otherNames>Walls GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BD85158B-4772-4230-BD85-F768591E9E9E"><gtr:id>BD85158B-4772-4230-BD85-F768591E9E9E</gtr:id><gtr:title>A mouse model for spondyloepiphyseal dysplasia congenita with secondary osteoarthritis due to a Col2a1 mutation.</gtr:title><gtr:parentPublicationTitle>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0fe10ebdb8ef07071e879e1ba8081ed4"><gtr:id>0fe10ebdb8ef07071e879e1ba8081ed4</gtr:id><gtr:otherNames>Esapa CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0884-0431</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E163AF88-DF2F-449D-9B66-E1D67EF0262D"><gtr:id>E163AF88-DF2F-449D-9B66-E1D67EF0262D</gtr:id><gtr:title>Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b52b61d3e3709d22522d044d591de5c9"><gtr:id>b52b61d3e3709d22522d044d591de5c9</gtr:id><gtr:otherNames>Thakker RV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D474CE34-B607-4512-B878-C14A02B9F245"><gtr:id>D474CE34-B607-4512-B878-C14A02B9F245</gtr:id><gtr:title>Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81b3b301eda9bae75b5845db1e012d7a"><gtr:id>81b3b301eda9bae75b5845db1e012d7a</gtr:id><gtr:otherNames>Medley L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9AC5A336-98D7-4C27-B851-56E8386F6DF2"><gtr:id>9AC5A336-98D7-4C27-B851-56E8386F6DF2</gtr:id><gtr:title>Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2fb3e361f4680064c89a62f1e0816aa4"><gtr:id>2fb3e361f4680064c89a62f1e0816aa4</gtr:id><gtr:otherNames>Hannan FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/24FC78D1-C1B5-48EE-BAD2-C6BF1A83B0A3"><gtr:id>24FC78D1-C1B5-48EE-BAD2-C6BF1A83B0A3</gtr:id><gtr:title>Investigating hypocalcaemia.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2fb3e361f4680064c89a62f1e0816aa4"><gtr:id>2fb3e361f4680064c89a62f1e0816aa4</gtr:id><gtr:otherNames>Hannan FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E1B13FA0-0A2B-490B-BB6B-363A620DF229"><gtr:id>E1B13FA0-0A2B-490B-BB6B-363A620DF229</gtr:id><gtr:title>Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c04409703a15a781751ba68128436aad"><gtr:id>c04409703a15a781751ba68128436aad</gtr:id><gtr:otherNames>Ramage JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E5C6DF74-2641-44D4-94EA-840697012096"><gtr:id>E5C6DF74-2641-44D4-94EA-840697012096</gtr:id><gtr:title>Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d10a0ee7ef278dd7fec416e497281585"><gtr:id>d10a0ee7ef278dd7fec416e497281585</gtr:id><gtr:otherNames>Yu W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A908FA53-45BB-4726-BD3F-18CF01FF0F55"><gtr:id>A908FA53-45BB-4726-BD3F-18CF01FF0F55</gtr:id><gtr:title>A G-protein Subunit-a11 Loss-of-Function Mutation, Thr54Met, Causes Familial Hypocalciuric Hypercalcemia Type 2 (FHH2).</gtr:title><gtr:parentPublicationTitle>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/be3d7fbaa94ddd1c4d54cd8939adddda"><gtr:id>be3d7fbaa94ddd1c4d54cd8939adddda</gtr:id><gtr:otherNames>Gorvin CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0884-0431</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D33A52E-B567-45B1-990D-4C93E0CBC22C"><gtr:id>0D33A52E-B567-45B1-990D-4C93E0CBC22C</gtr:id><gtr:title>Genetics of parathyroid tumours.</gtr:title><gtr:parentPublicationTitle>Journal of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b52b61d3e3709d22522d044d591de5c9"><gtr:id>b52b61d3e3709d22522d044d591de5c9</gtr:id><gtr:otherNames>Thakker RV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0954-6820</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/98FC3D8D-1D46-47EC-913C-96B6B2A6868B"><gtr:id>98FC3D8D-1D46-47EC-913C-96B6B2A6868B</gtr:id><gtr:title>Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4012bab03e044a389467d6bd29325d39"><gtr:id>4012bab03e044a389467d6bd29325d39</gtr:id><gtr:otherNames>Newey PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B3BBEC04-D751-47FE-9D0D-290442F4587A"><gtr:id>B3BBEC04-D751-47FE-9D0D-290442F4587A</gtr:id><gtr:title>An N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ff9ff780a2c6c6c409cf9d75f12ebab5"><gtr:id>ff9ff780a2c6c6c409cf9d75f12ebab5</gtr:id><gtr:otherNames>Bentley L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000467</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>